Ferring Pharmaceuticals AS has teamed up with private equity group Blackstone Life Sciences to create FerGene, a new company backed with over $570m to advance its investigational bladder cancer gene therapy nadofaragene firadenovec to the US market.
Blackstone is putting in $400m and Ferring will invest up to $170m in FerGene to advance nadofaragene firadenovec, which is in late-stage development for patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?